Hinge Health (NYSE:HNGE) Given New $134.00 Price Target at Canaccord Genuity Group

Hinge Health (NYSE:HNGE) had its price target raised by equities researchers at Canaccord Genuity Group from $105.00 to $134.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Canaccord Genuity Group‘s price target points to a potential upside of 16.41% from the stock’s previous close.

A number of other research analysts have also weighed in on the stock. Royal Bank Of Canada lifted their price target on shares of Hinge Health from $75.00 to $110.00 and gave the company an “outperform” rating in a research note on Wednesday, August 5th. Needham & Company LLC boosted their price objective on shares of Hinge Health from $115.00 to $135.00 and gave the company a “buy” rating in a research report on Tuesday. Citizens Jmp boosted their price objective on shares of Hinge Health from $96.00 to $107.00 and gave the company a “market outperform” rating in a research report on Wednesday, August 5th. Evercore reaffirmed an “outperform” rating and issued a $105.00 target price on shares of Hinge Health in a research note on Wednesday, August 5th. Finally, Zacks Research cut Hinge Health from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $113.53.

Hinge Health Trading Up 0.7%

NYSE:HNGE opened at $115.11 on Tuesday. The business’s 50-day moving average price is $98.66 and its two-hundred day moving average price is $67.35. Hinge Health has a 1-year low of $30.08 and a 1-year high of $118.87. The firm has a market capitalization of $9.29 billion, a price-to-earnings ratio of 89.93 and a beta of 1.37.

Hinge Health (NYSE:HNGE) last issued its earnings results on Monday, November 2nd. The company reported $0.71 EPS for the quarter, beating the consensus estimate of $0.27 by $0.44. The firm had revenue of $234.97 million during the quarter. Hinge Health had a net margin of 15.15% and a return on equity of 51.60%. The firm’s revenue for the quarter was up 52.4% on a year-over-year basis. During the same period in the previous year, the company posted ($0.02) EPS. Sell-side analysts predict that Hinge Health will post 1.25 earnings per share for the current year.

Insider Transactions at Hinge Health

In related news, President James Pursley sold 33,000 shares of Hinge Health stock in a transaction that occurred on Monday, September 21st. The stock was sold at an average price of $94.14, for a total transaction of $3,106,620.00. Following the completion of the sale, the president directly owned 666,909 shares of the company’s stock, valued at approximately $62,782,813.26. This trade represents a 4.71% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Perez sold 4,100 shares of the business’s stock in a transaction on Tuesday, October 6th. The shares were sold at an average price of $100.20, for a total value of $410,820.00. Following the completion of the sale, the chief executive officer owned 4,100 shares of the company’s stock, valued at $410,820. This trade represents a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 1,024,581 shares of company stock valued at $95,632,761. 18.92% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Hinge Health

Institutional investors and hedge funds have recently modified their holdings of the business. SBI Securities Co. Ltd. lifted its position in Hinge Health by 39.5% during the third quarter. SBI Securities Co. Ltd. now owns 364 shares of the company’s stock worth $35,000 after purchasing an additional 103 shares during the period. ProShare Advisors LLC increased its holdings in Hinge Health by 2.1% in the 3rd quarter. ProShare Advisors LLC now owns 5,588 shares of the company’s stock valued at $543,000 after buying an additional 117 shares during the period. IFP Advisors Inc increased its holdings in Hinge Health by 140.0% in the 2nd quarter. IFP Advisors Inc now owns 324 shares of the company’s stock valued at $27,000 after buying an additional 189 shares during the period. Janney Montgomery Scott LLC raised its position in shares of Hinge Health by 3.3% in the 1st quarter. Janney Montgomery Scott LLC now owns 9,400 shares of the company’s stock valued at $362,000 after buying an additional 300 shares in the last quarter. Finally, Nykredit A S acquired a new position in shares of Hinge Health in the 2nd quarter valued at approximately $29,000.

Key Stories Impacting Hinge Health

Here are the key news stories impacting Hinge Health this week:

• Positive Sentiment: Quarterly results exceeded consensus. Hinge Health generated approximately $235.0 million in revenue, up 52.4% year over year, and reported $0.71 in earnings per share versus estimates ranging from $0.27 to $0.63. The company also posted a 15.15% net margin, reinforcing the improving profitability story. Hinge Health reports record third quarter 2026 financial results
• Positive Sentiment: Management provided a constructive growth outlook. Hinge Health outlined 2026 revenue of $879 million to $881 million, representing another upward outlook adjustment according to coverage of the earnings call. The company also is targeting an integrated gastrointestinal care program for summer 2027, creating a potential new expansion opportunity beyond its core musculoskeletal business. Hinge Health outlines revenue outlook and GI program
• Neutral Sentiment: The earnings reaction was relatively limited. Although Hinge Health cleared published estimates and highlighted record results, reports characterized the stock’s response as muted. With a market capitalization near $9.3 billion, a price-to-earnings ratio around 89, and shares close to their one-year high, much of the strong execution may already be reflected in the valuation. Hinge Health third-quarter results beat forecasts
• Negative Sentiment: Expectations remain a key risk. Some coverage indicated that results missed the higher “whisper” forecast despite beating official consensus estimates. That gap, combined with the stock’s sharp appreciation above its 50-day and 200-day moving averages, could limit further gains unless Hinge Health continues delivering sizable revenue growth and upward guidance revisions. Hinge Health clears consensus but misses the whisper

Hinge Health Company Profile

Hinge Health is a digital healthcare company focused on musculoskeletal (MSK) conditions, including back and joint pain. The company provides virtual care programs designed to help members manage pain, improve mobility and reduce the need for more costly or invasive treatments.

Its platform combines personalized exercise therapy, behavioral support, education and access to clinical professionals. Hinge Health also uses technologies such as motion-sensing wearable devices and artificial intelligence to help guide exercises, monitor progress and tailor care plans to individual needs.

Hinge Health primarily serves employers and health plans, which offer its programs to eligible members in the United States.